Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil
Assis, Tália Santana Machado de; Rabello, Ana; Cota, Gláucia; Werneck, Guilherme Loureiro; Azeredo-da-Silva, André Luís Ferreira de.
Rev. Soc. Bras. Med. Trop
; 52: e20180272, 2019. tab, graf
Artigo
em Inglês
| LILACS | ID: biblio-1041550
Abstract
INTRODUCTION:
Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.METHODS:
A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies.RESULTS:
IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year.CONCLUSIONS:
These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.
Biblioteca responsável:
BR1.1
Texto completo
Documentos relacionados